Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Joint injection shows promise for stopping repeat bleeds in hemophilia

NCT ID NCT07187661

Disease control Sponsor: Khyber Medical University Peshawar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether injecting bevacizumab (a drug that blocks blood vessel growth) into the joints of people with hemophilia can prevent repeated bleeding episodes. Eighteen participants with chronic synovitis (joint inflammation) received the injection. Researchers measured changes in bleeding rates, joint health, and MRI scans over three months to see if the treatment reduced bleeds and improved joint condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bevacizumab (Avastin), a drug that blocks blood vessel growth
What this could lead to
If it works, this could offer a new way to reduce painful joint bleeds and improve joint health in people with hemophilia.
What could go wrong
This is a very small, early study with only 18 people and no comparison group. The effects may not be confirmed in larger trials, and there is a risk of side effects from the injection or the drug itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

18 people

The number who actually took part.

Started

Sep 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of Hemophilia A. * Presence of one or more target joints (knee, elbow, ankle) with chronic synovitis and a history of \>2 hemarthrosis episodes in the past 6 months. * Target joint World Federation of Hemophilia (WFH) joint score of 2-3. * Adequate hematological, renal, and liver function (as specified by protocol lab values). * Ability and willingness to provide informed consent and comply with the study protocol. Exclusion Criteria: * HIV positive diagnosis. * Severely damaged joints or anatomical limitations preventing safe injection. * Contraindications to MRI. * Uncontrolled hypertension. * Recent major surgery/trauma (\<28 days). * Serious non-healing wound, active cardiovascular disease, or other significant comorbidities that could increase risk or interfere with the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic synovitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemophilia hemophilia A synovitis hemarthrosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic synovitis Hemophilia

Contacts and locations

Locations

  • Hayatabad Medical Complex

    Peshawar, KPK, 25000, Pakistan

  • Institute of Pathology and Diagnostic Medicine (IPDM)

    Peshawar, KPK, 25000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.